Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Much Of Telemed Legislation Emerging From New Congress Would Only Partially Solve Payment Woes

Executive Summary

A telemedicine legislative expert explains provisions of bills that would expand reimbursement provisions in Congress.

You may also be interested in...

Expanding Medicare Coverage For Digital Health Technologies Gains Support

AdvaMed outlined recommendations to expand Medicare coverage for digital health tech. Several lawmakers are also pushing to retain flexibilities after the COVID-19 public health emergency expires.

ATA Throws Weight Behind Renewed Telehealth Bill In New Session Of Congress

One of the first US telemed bills out of the gate in 2021 calls for permanently ending limits on CMS telehealth payments.

US House Panel Passes Telehealth, Counterfeit Device, National Stockpile Bills In Marathon Mark-Up

The House Energy and Commerce Committee swiftly passed three measures impacting medtech companies during a 15 July mark-up session.


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts